--- a
+++ b/clusters/9knumclustersv2/clust_1551.txt
@@ -0,0 +1,45 @@
+Histologically confirmed metastatic colorectal cancer, not amenable to curative resection
+Histologically or cytologically confirmed GI malignancy for which mFOLFOX is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)
+Measurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC).
+Pathologically documented diagnosis of colorectal adenocarcinoma.
+Histologically confirmed unresectable metastatic colorectal adenocarcinoma
+Histologically confirmed colorectal adenocarcinoma
+Patients must have histologically or cytologically confirmed metastatic colorectal cancer.
+Have histologically confirmed, locally advanced unresectable or metastatic (stage IV) colorectal adenocarcinoma
+For patients with metastatic colorectal cancer:\r\n* Stage IV histologically-proven colorectal adenocarcinoma\r\n* Liver metastasis confirmed to be surgically resectable, with surgery evaluation and planned resection; may have minimal extrahepatic disease that is determined to be resectable\r\n* Tumor must be confirmed to be microsatellite stable (MSS); if not already reported at a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, we will be able to perform this at Emory University\r\n* No prior immunotherapy\r\n* No cancer chemotherapy treatment  weeks prior to day  of treatment
+Histologically confirmed diagnosis of colorectal adenocarcinoma
+Patients must have histologically and or cytologically confirmed metastatic colorectal cancer
+Participants must have histologically or cytologically confirmed adenocarcinoma of colorectal or pancreatic origin
+Histologically confirmed colorectal cancer
+Have a diagnosis of histologically confirmed metastatic colorectal cancer to the liver (no other sites of metastatic disease)\r\n* Histologic confirmation of a colorectal primary tumor is acceptable if accompanied by radiographic evidence of metastatic disease
+Patients with histologically confirmed KRAS positive metastatic colorectal cancer
+Histologically or cytologically confirmed metastatic colorectal adenocarcinoma (colon, rectal, colorectal, appendiceal cancer) or small bowel that is not resectable
+Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma
+Histologically or cytologically confirmed colorectal adenocarcinoma.
+Histologically or cytologically confirmed colorectal adenocarcinoma
+Histologically confirmed unresectable metastatic colorectal adenocarcinoma
+Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies
+Histologically confirmed stage IV colorectal adenocarcinoma without any prior systemic treatment
+Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary colorectal and appendiceal tumors
+Locally confirmed dMMR or MSI-H stage IV colorectal carcinoma
+Histologically confirmed recurrent or metastatic colorectal cancer
+Histologically proven colorectal adenocarcinoma
+Patients with histologically confirmed metastatic colorectal cancer, who have received and/or progressed on a prior oxaliplatin-based chemotherapy regimen
+Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option
+Cohort A: patients with histologically proven metastatic or locally advanced MSI colorectal adenocarcinoma
+Cohort B: patients with histologically proven metastatic or locally advanced microsatellite stable (MSS) colorectal adenocarcinoma
+A histologically or cytologically confirmed colorectal cancer that is metastatic, unresectable, or recurrent.
+Patients must have histologically confirmed adenocarcinoma of colorectal origin that is metastatic or locally advanced and unresectable
+History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed by the enrolling institution
+Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric (including GE junction), colorectal, or pancreatic adenocarcinoma.
+Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a product related mutation in Ras (GV, GC, GD, GR, QL, QR, QH)
+Patients with histologically proven, unresectable, evaluable metastatic colorectal cancer, by RECIST criteria
+Histologically confirmed colorectal cancer with at least one measurable metastatic lesion by RECIST v ., that is considered unresectable at baseline
+Histologically confirmed colorectal cancer
+Histologically or cytologically confirmed refractory colorectal cancer
+Histologically or cytologically confirmed colorectal adenocarcinoma
+Patients must have histologically confirmed, radiologically measurable metastatic or locally advanced unresectable colorectal adenocarcinoma that is amenable to image-guided biopsy; disease in previously radiated regions may not be considered measurable unless there has been demonstrated progression in the lesion
+Histologically/cytologically proven colorectal carcinoma
+Histologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastases
+Patients must have histologically or cytologically confirmed colorectal or pancreatic carcinoma
+Histologically confirmed diagnosis of colorectal adenocarcinoma